0.00Open1.84Pre Close0 Volume6 Open Interest17.50Strike Price0.00Turnover3079.62%IV18.01%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry1.84Extrinsic Value100Contract SizeAmericanOptions Type-0.3830Delta0.0670Gamma10.38Leverage Ratio-29.9080Theta0.0000Rho-3.98Eff Leverage0.0007Vega
Cullinan Therapeutics Stock Discussion
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
• $Cullinan Therapeutics(CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin(APP.US)$ +15.5%(In reaction to earnings)
• $SmartRent(SMRT.US)$ +15.4%(In reaction to earnings)
• $Coupang(CPNG.US)$ +14.3%(In reaction to earn...
No comment yet